NO-SPA 0.04 x 20 tablets biliary tract disease

AVENTIS SANOFI


£7.99 £15.00




  • No-Spa is indicated takiech symptoms as smooth muscle contraction conditions associated with biliary tract disease, conditions of smooth muscle contraction of the urinary tract. Auxiliary in spastic gastrointestinal smooth muscle.

Composition:
1 tablet. It contains 40 mg drotaweryny. Action: Synthetic drug action spazmolitycznym. Action relaxants drotaweryny not depend on the type and location of the innervation of smooth muscle (gastrointestinal tract, urogenital system, circulatory system and bile ducts). The mechanism of action plays a role drotaweryny effect on phosphodiesterase, causing an increase in cAMP levels and the reduction and the calcium ion concentration in the cell. After oral administration of the drug is well absorbed from the gastrointestinal tract. It is metabolized in the liver. It is mainly excreted in the urine and to a lesser extent in bile. Indications: United contraction of smooth muscles associated with diseases of bile ducts: biliary lithiasis, cholecystitis, okołopęcherzykowym inflammation, inflammation of the bile ducts, inflammation of the papilla of Vater.United contraction of smooth muscles of the urinary tract: kidney stones, kidney ureters, pyelitis, cystitis, painful urge to urinate.Auxiliary in spastic smooth muscle of the gastrointestinal tract: peptic ulcer of the stomach and duodenum, gastritis, enteritis, colitis, the spastic cardia and pyloric stomach, irritable bowel syndrome, constipation against flatulence and spastic bowel, inflammation of the pancreas; in spastic within the genital tract: in dysmenorrhea, inflammation appendages, strong labor pains, threatening abortion;headaches of vascular origin. Contraindications: Hypersensitivity to any of the ingredients. Severe hepatic failure, renal impairment.Heart failure. Atrioventricular block II ° and III °. Pregnancy and lactation: Pregnant and breast-feeding apply only if the benefits outweigh the potential risks (lack of sufficient research). Interactions: Caution should be used when co-administered with levodopa due to reduce its activities przeciwparkinsonowego and severity of tremors and rigidity. Dosage: Oral. Adults 120-240 mg daily in 2-3 doses.Children 2-6 years of age - 40-120 mg daily in 2-3 doses; over 6 years of age 80-200 mg per day in 2-5 doses.


Share this Product